A Phase 1b, Randomized, Controlled, Double-blind Trial To Evaluate The Safety And Immunogenicity Of Multivalent Pneumococcal Conjugate Vaccines In Healthy Japanese Adults 18 To 49 Years Of Age
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2018
At a glance
- Drugs Pneumococcal vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 08 Oct 2018 Planned End Date changed from 24 Apr 2019 to 25 Mar 2019.
- 08 Oct 2018 Planned primary completion date changed from 24 Apr 2019 to 25 Mar 2019.
- 08 Oct 2018 Status changed from recruiting to active, no longer recruiting.